Last reviewed · How we verify
Thiodrol (EPITIOSTANOL)
Thiodrol (generic name: EPITIOSTANOL) is a drug. It is currently in Phase 2 development.
Thiodrol works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a potent form of testosterone.
Thiodrol, also known as Epitiostanol, is a small molecule modality with unknown drug class and target. Its commercial status is unclear, and it is not FDA approved for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its efficacy and safety profile. It is currently owned by an unknown entity.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | EPITIOSTANOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
Think of it like a traffic cop: Thiodrol blocks the road that leads to DHT, a hormone that can contribute to conditions like prostate enlargement and hair loss. By reducing DHT levels, Thiodrol may help alleviate symptoms associated with these conditions. This is a simplified explanation of a complex biochemical process.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thiodrol CI brief — competitive landscape report
- Thiodrol updates RSS · CI watch RSS
Frequently asked questions about Thiodrol
What is Thiodrol?
How does Thiodrol work?
What is the generic name of Thiodrol?
What development phase is Thiodrol in?
Related
- Therapeutic area: All drugs in Urology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing